Trump Signs 100 Percent Tariff on Branded Pharmaceuticals — One Year After Liberation Day

President Trump signed a proclamation on April 2, 2026, imposing tariffs of up to 100 percent on imported patented pharmaceuticals and their active ingredients. The action, taken under Section 232 of the Trade Expansion Act, arrives exactly one year after the administration's sweeping Liberation Day tariffs and opens a new front in the ongoing trade confrontation.

How the Tariff Structure Works

The headline rate is 100 percent, but the structure is layered with exemptions and off-ramps designed to push pharmaceutical companies toward domestic manufacturing and pricing agreements.

Companies that have signed Most Favored Nation pricing deals with the Department of Health and Human Services and committed to building manufacturing facilities in the United States face a zero percent tariff through January 2029. Companies that commit to onshoring production but have not yet completed pricing deals face a 20 percent rate, which would escalate to 100 percent in four years. Companies with no pricing deal and no domestic manufacturing plans face the full 100 percent rate.

Several major trading partners have negotiated separate frameworks. The European Union, Japan, South Korea, and Switzerland face a 15 percent rate. The United Kingdom faces a 10 percent rate under its existing pharmaceutical trade agreement.

Generic drugs, biosimilars, and orphan drugs are exempt from the tariffs at this time, though the administration has said it will reassess generic drug tariffs within one year.

Industry Response

The pharmaceutical trade group PhRMA criticized the tariffs immediately. Its CEO Stephen Ubl argued that tariffs on medicines will increase costs and could put at risk billions of dollars in domestic investments already announced. He noted that two-thirds of medicines consumed in the United States are already manufactured domestically, and that imported drugs overwhelmingly come from allied nations.

More than a dozen major drugmakers — including Pfizer, Eli Lilly, and Novo Nordisk — had already struck voluntary pricing deals with the administration over the past year. The tariff proclamation creates financial pressure on companies that have not yet made similar agreements.

The tariffs take effect in 120 days for larger companies and 180 days for smaller firms, giving the industry a window to negotiate.

Mubboo's Take

Drug pricing directly affects household budgets. Whether these tariffs ultimately lower or raise consumer costs depends on how many pharmaceutical companies choose to negotiate pricing deals versus absorb or pass along the tariffs. For consumers tracking health expenses, the practical effect will not be visible for months — but the direction of travel is clear: pharmaceutical pricing is becoming a trade policy instrument, not just a healthcare policy question.